Tatsuya Hayashi1, Satoshi Saitoh1, Yoshinori Tsuji1, Junji Takahashi1, Naomi Tagaya1, Mariko Hiramoto1, Kei Fukuzawa1, Masakatsu Tano1, Tosiaki Miyati1, Hiromitsu Kumada1. 1. From the Department of Radiological Technology (T.H., Y.T., J.T., N.T., M.H., K.F., M.T.), Okinaka Memorial Institute for Medical Research (T.H., S.S., Y.T., J.T., N.T., M.H., K.F., M.T., H.K.), Department of Hepatology (S.S., H.K.), and Department of Radiology (S.S.), Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan; and Division of Health Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan (T.H., T.M.).
Abstract
PURPOSE: To investigate whether gadoxetate disodium affects peripheral capillary oxygen saturation (SpO2) and/or heart rate (HR) during dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging in patients with liver diseases. MATERIALS AND METHODS: This retrospective study was approved by the institutional review board, who waived the requirement for informed consent. Four hundred fifty-eight patients (171 women [mean age, 66.5 years; range, 23-87 years] and 287 men [mean age, 61.1 years; range, 25-89 years]) who underwent liver DCE MR imaging with gadoxetate disodium (0.025 mmol per kilogram of body weight) from October 28, 2013, to June 24, 2014, were included in this study. They were monitored for SpO2 and HR during DCE MR imaging. Motion artifact severity was graded by using a five-point scale, and transient severe motion (TSM) was defined by a score of at least 4. The association between TSM and baseline predictors was assessed, and HR and SpO2 at each postcontrast phase were compared with those at the precontrast phase in the TSM and non-TSM groups. RESULTS: Four hundred thirty-six patients were included in the non-TSM group, and 22 were included in the TSM group. Although the motion score was the worst at the arterial phase, the observed mean differences in SpO2 and HR between the precontrast phase and the arterial phase were less than 1% and 5 beats per minute, respectively (mean SpO2 ± standard deviation for the non-TSM group, 96.7% ± 1.8 vs 96.9% ± 1.8 [P = .11]; SpO2 for the TSM group, 96.4% ± 1.6 vs 96.1% ± 1.6 [P > .99]) (HR for the non-TSM group, 68.9 beats per minute ± 12.4 vs 70.9 beats per minute ± 12.1 [P < .0001]; HR for the TSM group, 75.0 beats per minute ± 11.8 vs 79.9 beats per minute ± 10.2 [P < .0001]). CONCLUSION: Intravenous gadoxetate disodium (a weight-based dose) does not cause changes in SpO2 and HR that lead to image quality degradation.
PURPOSE: To investigate whether gadoxetate disodium affects peripheral capillary oxygen saturation (SpO2) and/or heart rate (HR) during dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging in patients with liver diseases. MATERIALS AND METHODS: This retrospective study was approved by the institutional review board, who waived the requirement for informed consent. Four hundred fifty-eight patients (171 women [mean age, 66.5 years; range, 23-87 years] and 287 men [mean age, 61.1 years; range, 25-89 years]) who underwent liver DCE MR imaging with gadoxetate disodium (0.025 mmol per kilogram of body weight) from October 28, 2013, to June 24, 2014, were included in this study. They were monitored for SpO2 and HR during DCE MR imaging. Motion artifact severity was graded by using a five-point scale, and transient severe motion (TSM) was defined by a score of at least 4. The association between TSM and baseline predictors was assessed, and HR and SpO2 at each postcontrast phase were compared with those at the precontrast phase in the TSM and non-TSM groups. RESULTS: Four hundred thirty-six patients were included in the non-TSM group, and 22 were included in the TSM group. Although the motion score was the worst at the arterial phase, the observed mean differences in SpO2 and HR between the precontrast phase and the arterial phase were less than 1% and 5 beats per minute, respectively (mean SpO2 ± standard deviation for the non-TSM group, 96.7% ± 1.8 vs 96.9% ± 1.8 [P = .11]; SpO2 for the TSM group, 96.4% ± 1.6 vs 96.1% ± 1.6 [P > .99]) (HR for the non-TSM group, 68.9 beats per minute ± 12.4 vs 70.9 beats per minute ± 12.1 [P < .0001]; HR for the TSM group, 75.0 beats per minute ± 11.8 vs 79.9 beats per minute ± 10.2 [P < .0001]). CONCLUSION: Intravenous gadoxetate disodium (a weight-based dose) does not cause changes in SpO2 and HR that lead to image quality degradation.
Authors: Andreas Gutzeit; Simon Matoori; Johannes M Froehlich; Constantin von Weymarn; Carolin Reischauer; Orpheus Kolokythas; Matthias Goyen; Klaus Hergan; Matthias Meissnitzer; Rosemarie Forstner; Jan D Soyka; Aleksis Doert; Dow-Mu Koh Journal: Eur Radiol Date: 2015-11-16 Impact factor: 5.315
Authors: Luigi Grazioli; Riccardo Faletti; Barbara Frittoli; Giacomo Battisti; Roberta Ambrosini; Laura Romanini; Marco Gatti; Paolo Fonio Journal: Radiol Med Date: 2018-08-06 Impact factor: 3.469
Authors: Kristina I Ringe; Christian von Falck; Hans-Jürgen Raatschen; Frank Wacker; Jan Hinrichs Journal: PLoS One Date: 2018-07-19 Impact factor: 3.240